Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts

Pharma By Jessica Davis Plüss

European researchers seek greater stake in drug development in bid to improve access

The effort has had some success with medicines destined for low-income countries, but has faced hurdles in Europe itself.

Read The Story

Biotech By Matthew Herper and Jason Mast

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations

Biotech By Jonathan Wosen and Akila Muthukumar

Eli Lilly wins FDA approval for first-ever treatment for hair loss caused by autoimmunity

Biotech By Adam Feuerstein

Canada approves ALS drug from Amylyx Pharma as U.S. patients await extended review

Biotech By Jonathan Wosen

Biotech is practically in San Diego’s DNA. Here’s how it got there — and how it might evolve

All Coverage

Biotech By Adam Feuerstein

PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval

Pharma By Adam Feuerstein

A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

Biotech By Allison DeAngelis

Third Rock Ventures plots next chapter after raising $1.1 billion fund

Adam's Take By Adam Feuerstein

Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

Biotech By Jason Mast

In early trial, drug shrinks tumors in majority of children with most common form of brain cancer

Biotech By Adam Feuerstein

Updated study results show a CRISPR treatment for blood diseases continues to benefit patients

Biotech By Damian Garde

FDA advisers endorse Bluebird gene therapy for rare blood disorder

Biotech By Matthew Herper

GSK says RSV vaccine for older adults ‘offers exceptional protection’

Biotech By Damian Garde

FDA advisers unanimously endorse Bluebird’s gene therapy for rare disorder

Biotech By Allison DeAngelis

Biospring Partners closes $245 million first fund as private markets tense up

Biotech By Matthew Herper

Moderna says Omicron-containing booster outperforms current vaccine

Biotech By Matthew Herper

Watch: An interview with the FDA’s top cancer regulator

Adam's Take By Adam Feuerstein

A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy

Biotech By Damian Garde

Praxis’ novel antidepressant fails make-or-break trial

Biotech By Adam Feuerstein

Adicet ‘gamma-delta’ T cell therapy shows complete remissions in early study of lymphoma patients

Biotech By Matthew Herper

With the right molecular signal, a cancer drug works in every patient

Pharma By Adam Feuerstein

Roche’s TIGIT troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target

Biotech By Angus Chen

Promising results reported for new generation of CAR-T immunotherapy for myeloma

Biotech By Matthew Herper

Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients

Biotech By Adam Feuerstein

In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients

Biotech By Adam Feuerstein

The FDA’s Pazdur on accelerated approval, single-arm studies, and his own future

Biotech By Matthew Herper

Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations

Biotech By Allison DeAngelis and Jason Mast

Neumora, ambitious startup focused on neuroscience, considers filing for an IPO

Biotech By Angus Chen

European researchers seek greater stake in drug development in bid to improve access

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations

Eli Lilly wins FDA approval for first-ever treatment for hair loss caused by autoimmunity

Canada approves ALS drug from Amylyx Pharma as U.S. patients await extended review

Biotech is practically in San Diego’s DNA. Here’s how it got there — and how it might evolve

All Coverage

PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval

A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

Third Rock Ventures plots next chapter after raising $1.1 billion fund

Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

In early trial, drug shrinks tumors in majority of children with most common form of brain cancer

Updated study results show a CRISPR treatment for blood diseases continues to benefit patients

FDA advisers endorse Bluebird gene therapy for rare blood disorder

GSK says RSV vaccine for older adults ‘offers exceptional protection’

FDA advisers unanimously endorse Bluebird’s gene therapy for rare disorder

Biospring Partners closes $245 million first fund as private markets tense up

Moderna says Omicron-containing booster outperforms current vaccine

Watch: An interview with the FDA’s top cancer regulator

A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy

Praxis’ novel antidepressant fails make-or-break trial

Adicet ‘gamma-delta’ T cell therapy shows complete remissions in early study of lymphoma patients

With the right molecular signal, a cancer drug works in every patient

Roche’s TIGIT troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target

Promising results reported for new generation of CAR-T immunotherapy for myeloma

Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients

In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients

The FDA’s Pazdur on accelerated approval, single-arm studies, and his own future

Bristol Myers Squibb to buy Turning Point Therapeutics for $4.1 billion to gain drugs targeting rare cancer mutations

Neumora, ambitious startup focused on neuroscience, considers filing for an IPO

Companies can’t make CAR-T cells for cancer treatment quickly enough. Here’s what they’re doing about it

Subscribe to STAT for $15 per month lorem ipsum